Renovaro Biosciences

Quarterly Financials

Values in thousands 2025-06-30 2025-03-31 2024-12-31 2024-09-30
Revenue
$0
$0
$0
$181
Gross Profit
-31
-32
-32
EBITDA
409
-7,121
-43,929
EBIT
377
-7,153
-43,961
Net Income
-126,732
189
-7,252
-44,212
Net Change In Cash
0
0
0
181
Free Cash Flow
-1,811
11,804,307,399
-2,559
-2,016
Cash
92
923
311
220
Basic Shares
17,739
16,393
16,182
15,656

Annual Financials

Values in thousands 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Revenue
$0
$0
$0
$0
Gross Profit
-121
-121
-113
-123
EBITDA
-81,517
-79,516
-19,483
-22,702
EBIT
-81,639
-79,638
-19,596
-22,826
Net Income
-80,650
-80,650
-39,684
-113,433
Net Change In Cash
0
0
0
0
Free Cash Flow
-11,041
-11,041
-11,804
-15,737
Cash
220
220
1,874
9,172
Basic Shares
9,624
96,248
5,626
5,252

Earnings Calls

Quarter EPS
2025-06-30
-$7.60
2025-03-31
$0.001
2024-12-31
-$0.04
2024-09-30
-$0.28